Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the MSI-H And dMMR Market Size Changed, over the years?

The market size for MSI-H and dMMR has seen a rapid surge in the past few years. This market is projected to increase from $6.15 billion in 2024 to $7.59 billion in 2025, growing at a compound annual growth rate (CAGR) of 23.3%. Factors contributing to this demand during the historic period include a higher occurrence of colorectal and endometrial cancers, the expansion of genetic screening programs, greater clinical implementation of MSI testing, rising awareness regarding hereditary cancer syndromes, and the increasing acceptance of liquid biopsy.

How Much Will the MSI-H And dMMR Market Be Worth in 2029?

The market for MSI-H and dMMR is projected to expand significantly in the coming years, reaching a value of $17.40 billion in 2029 with a compound annual growth rate of 23.1%. This anticipated growth during the forecast period is due to factors such as the rising preference for tailored cancer treatments, the broadening scope of next-generation sequencing, increasing investment in cancer care, the proliferation of clinical trials for immune checkpoint inhibitors, and regulatory backing for companion diagnostics. The forecast period is also expected to see trends like the incorporation of artificial intelligence in diagnostic procedures, collaborations between pharmaceutical and diagnostic firms, the creation of multiplex biomarker panels, breakthroughs in immunotherapy, and a shift towards pan-cancer biomarker testing.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

Which is the Largest Company in the MSI-H And dMMR Market?

Major companies operating in the MSI-H and dMMR market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

What Are the Main Market Drivers in the MSI-H And dMMR Industry?

The acceleration in incidences of cancer is anticipated to boost the expansion of the MSI-H and dMMR market. Cancer is a collection of disorders distinguished by uncontrolled and unregulated growth and dissemination of abnormal body cells. This increase in incidences of cancer is mainly attributable to aging populations, since the chances of having cancer escalate considerably with age due to a combined effect of genetic mutations and prolonged exposure to threat factors over time. MSI-H and dMMR serve in cancer to spot tumors with high mutation frequencies because of defects in DNA rectification mechanisms. These biomarkers are beneficial in guiding immunotherapy decisions since such tumors are more probable to respond to immune checkpoint inhibitors, and they also offer insights into prognosis and possible genetic syndromes. For example, as per the American Cancer Society, a non-profit organization in the US, there were approximately 1,958,310 newly diagnosed cancer cases and 609,820 cancer-related fatalities predicted in the United States in 2023. These statistics are expected to surge in 2024, with around 2,001,140 new cancer instances and 611,720 deaths anticipated, indicating a continuous uprise in cancer occurrence and mortality. Consequently, the escalating prevalence of cancer propels the expansion of the MSI-H and dMMR market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

How Is the MSI-H And dMMR Market Segments Structured?

The MSI-H and dMMR market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

What Strategic Trends Are Transforming the MSI-H And dMMR Market?

Key players in the MSI-H and dMMR market are concentrating on creating cutting-edge treatments, such as combination therapy, to boost the effectiveness of treatments and enhance patient results. Combination therapy for MSI-H and dMMR cancers typically involves the use of several treatment methods, such as immunotherapy treatments like checkpoint inhibitors or combining immunotherapy with chemotherapy, targeted therapy, or radiation. This method is aimed at increasing treatment responsiveness, overcoming resistance, and boosting patient survival rates with tumors that show high microsatellite instability or deficient mismatch repair. For example, in April 2025, the American pharmaceutical company, Bristol-Myers Squibb Company, was granted approval by the United States Food and Drug Administration (FDA) to combine nivolumab (Opdivo) and ipilimumab (Yervoy) as an initial treatment for metastatic colorectal cancer (mCRC) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) characteristics, thus expanding treatment possibilities for this difficult cancer subtype. This approval is a notable milestone in the treatment of MSI-H and dMMR cancers, offering a novel, effective treatment option that targets several pathways to boost patient survival and response rates, meeting the unfulfilled medical needs of this patient group.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

Which Global Regions Offer the Highest Growth in the MSI-H And dMMR Market?

North America was the largest region in the MSI-H and dMMR market in 2024. The regions covered in the MSI-H and dMMR market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/customise?id=24324&type=smp

This Report Delivers Insight On:

1. How big is the msi-h and dmmr market, and how is it changing globally?

2. Who are the major companies in the msi-h and dmmr market, and how are they performing?

3. What are the key opportunities and risks in the msi-h and dmmr market right now?

4. Which products or customer segments are growing the most in the msi-h and dmmr market?

5. What factors are helping or slowing down the growth of the msi-h and dmmr market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model